Diagnostic Center | May 20, 2024
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi approved by USFDA
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Achira is engaged in development and commercialization of PoC medical test kits in India
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
Subscribe To Our Newsletter & Stay Updated
